There are currently 50 active clinical trials seeking participants for Systemic Lupus Erythematosus research studies. The states with the highest number of trials for Systemic Lupus Erythematosus participants are California, Florida, Texas and New York.
REACT-01: Reversing Autoimmunity Through Cell Therapy
NCT06465147
Recruiting
This is a phase 1, open-label, non-randomized study enrolling pediatric and young adult research participants with treatment-refractory Systemic Lupus Erythematosus (SLE), to examine the safety, feasibility, and efficacy of administering T cell products derived from peripheral blood mononuclear cells (PBMC) that have been genetically modified to express CD19 specific chimeric antigen receptor (CAR) A child or young adult meeting all eligibility criteria and meeting none of the exclusion criteri... Read More
Gender:
ALL
Ages:
Between 2 years and 30 years
Trial Updated:
10/30/2024
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Systemic Lupus Erythematosus
Register for Updates
The HOP-STEP Intervention: Improving Maternal Health in Women With Lupus sIRB
NCT05818254
Recruiting
While the HOP-STEP (Healthy Outcomes in Pregnancy with SLE Through Education of Providers) program has been demonstrated to be effective in improving provider confidence, increasing contraception documentation, and facilitating equitable pregnancy planning care in a single sub-specialty clinic here at Duke, the delivery of HOP-STEP may need to be changed to increase its fit with the local context at the University of Chicago Medical Center (UCMC) and subsequent locations. Thus, the investigators... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2024
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Systemic Lupus Erythematosus, Contraception
Register for Updates
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)
NCT06456567
Recruiting
The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of moderately to severely active SLE.
Gender:
ALL
Ages:
Between 12 years and 70 years
Trial Updated:
09/13/2024
Locations: Hemet site, Hemet, California +3 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
NCT06581562
Recruiting
This study will evaluate the safety and activity of AB-101 in combination with rituximab in B-cell associated autoimmune diseases where rituximab is currently FDA approved (e.g., Rheumatoid Arthritis (RA), Pemphigus Vulgaris (PV), Granulomatosis with polyangiitis (GPA)/microscopic polyangiitis (MPA) as a therapeutic, or is recommended (e.g., in Systemic Lupus Erythematosus (SLE) as a cornerstone for disease management.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2024
Locations: IRIS Research and Development, LLC, Plantation, Florida
Conditions: Rheumatoid Arthritis, Pemphigus Vulgaris, Granulomatosis With Polyangiitis, Systemic Lupus Erythematosus
Register for Updates
The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
NCT05540327
Recruiting
The purpose of the study is to evaluate the long term safety and efficacy of orally administered M5049 in participants with subacute cutaneous lupus erythematosus (SCLE), discoid lupus erythematosus (DLE) and/or systemic lupus erythematosus (SLE) who have completed the 24 week treatment period of Willow study (MS200569_0003 \[NCT05162586\]).
Gender:
ALL
Ages:
Between 18 years and 76 years
Trial Updated:
08/07/2024
Locations: The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California +122 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
FT819 in Moderate to Severe Active Systemic Lupus Erythematosus
NCT06308978
Recruiting
This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following treatment with or without auxiliary medicinal product (AMP) in participants with moderate to severe active systemic lupus erythematosus (SLE). The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT819.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2024
Locations: University of Minnesota Medical School, Minneapolis, Minnesota +1 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
NCT06518668
Recruiting
Primary objective: Safety and tolerability of NKX019, administered after lymphodepletion (LD). Secondary objectives: * Assess clinical activity of NKX019 in subjects with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN) * Characterize pharmacokinetics (PK) of NKX019 * Characterize immunogenicity of NKX019
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/19/2024
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Systemic Lupus Erythematosus
Register for Updates
Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions
NCT04833465
Recruiting
The overarching goal of this study is the development of a physiologic endpoint of pain and treatment effect in three distinct rheumatology populations. This would enable objective assessment of pain and treatment in these populations and enable a much more precise approach to treatment. Such an endpoint stands to significantly improve outcomes in these patients by eliminating the need for a trial-and-error approach to treatment. This is a single site observational study that aims to collect ini... Read More
Gender:
ALL
Ages:
Between 5 years and 21 years
Trial Updated:
07/03/2024
Locations: Children's National Health System, Washington, District of Columbia
Conditions: Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus, Fibromyalgia
Register for Updates
Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
NCT05799378
Recruiting
Hydroxychloroquine (HCQ) is a systemic lupus erythematosus (SLE) medication that has been very effective in reducing lupus disease activity and keeping patients stable with reduced symptoms. Despite a track record of safety with regard to infection compared to traditional immunosuppressive agents, the risk of HCQ retinal toxicity escalates with continued use. Evaluation using sensitive standard of care approaches suggests nearly a third of patients accrue retinal damage. Data are needed to accur... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
06/27/2024
Locations: University of California, Los Angeles, Los Angeles, California +9 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
REACH (Restore Energy, Activity Can Help) Lupus Study
NCT06479213
Recruiting
The goal of this clinical trial is to pilot test the REACH peer coaching program for fatigue in people with systemic lupus erythematosus. The main questions it aims to answer are: 1. Is the REACH program feasible and acceptable to participants? 2. What is the impact of the REACH program on fatigue? Researchers will compare the REACH peer coaching program to the REACH mobile health application to see if the REACH program works to reduce fatigue. Participants will: * Use the REACH mobile healt... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2024
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Systemic Lupus Erythematosus, Fatigue
Register for Updates
Lupus Education Alliance Program
NCT05243875
Recruiting
The purpose of this study is to evaluate the evaluate the effect of education-only vs. navigation interventions on COVID-19 testing and vaccination for people with systemic lupus erythematosus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2024
Locations: Tulane University, New Orleans, Louisiana
Conditions: Systemic Lupus Erythematosus, COVID-19
Register for Updates
Electroencephalogram Recording in Patients With Systemic Lupus Erythematosus
NCT06378736
Recruiting
Patients with systemic lupus erythematosus (SLE) often experience a frustrating decline of their cognitive skills that includes considerable problems in attention, learning, and memory. This lupus-related cognitive dysfunction (termed SLE-CD) is recognized as the most prevalent of the nineteen neuropsychiatric SLE syndromes, as it affects up to 80% of patients and can significantly decrease their quality of life. The goal is to have tools that can be used for diagnosis and for monitoring respons... Read More
Gender:
Female
Ages:
Between 18 years and 65 years
Trial Updated:
04/25/2024
Locations: Northwell Health-Feinstein Insitute, Manhasset, New York
Conditions: Systemic Lupus Erythematosus
Register for Updates